# A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients

> **NCT04004910** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Immunicom Inc** · enrollment: 170 (estimated)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **OTHER:** Plasma soluble TNF receptor pulldown
- **OTHER:** Plasma soluble TNF receptor pulldown + chemotherapy
- **DRUG:** Chemotherapy Drugs, Cancer

## Key facts

- **NCT ID:** NCT04004910
- **Lead sponsor:** Immunicom Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-31
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-07-31
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2022-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04004910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04004910, "A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04004910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*